Connect with us

POZ

Hans: Life goes on and still has a lot of good things for PLHIVs

Meet contributing writer Hans, who discovered his HIV-positive status in 2013. He used to feel sorry for himself, but realized he had to remain strong to face what lies ahead. “Life must go on and it store a lot of good things for us. Define your true purpose in life that you may be whole,” he says.

Published

on

This is part of “More than a Number”, which Outrage Magazine launched on March 1, 2013 to give a human face to those infected and affected by the Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in the Philippines, what it considers as “an attempt to tell the stories of those whose lives have been touched by HIV and AIDS”. More information about (or – for that matter – to be included in) “More than a Number”, email editor@outragemag.com, or call (+63) 9287854244 and (+63) 9157972229.

It was November of 2013 when an insurance underwriter went to my office and offered me an investment/insurance. However, for me to be able to obtain such insurance, one requirement was to be tested for HIV.

I declined and told the underwriter if the insurance have a contestability period for me not to undergo such test. To cut the story short, I got the insurance without the medical requirement.

Days passed, I felt uneasy and I wanted to make sure if I was really clear from HIV. And for me to know, I had to get tested. It took me so much courage that I embraced the fact of being tested and just accept my fate whatever the result might be.

I went to Hi-Precision in Kalaw (in the City of Manila). I told the front desk nurse that I wanted to be tested. He gave me a form to fill in. I was a bit hesitant to answer it, but I must, in able to help myself deal with the uncertainty. After filling in the confidential disclosure form, I had a quick blood extraction. The nurse told me to call back after a week for the result.

It’s the due date and I called the health service provider. They told me to call back again after a week. It somehow gave me a feeling of anxiety. But still, I thought of having the best of health. I had no idea that my result was on its way to being confirmed by the STD AIDS Cooperative Central Laboratory (SAACL) of San Lazaro Hospital.

MOMENT OF TRUTH

November 23, 2013 – the moment of truth. I asked for my result and the nurse told me to patiently wait. All I can recall was that most of the nurses were looking at me in a peculiar manner. It took some time before they called me again. Another nurse assisted me at the second floor. She was carrying a sealed enveloped. Every second made my heart pound. Anxiety was gripping me and it took me so long to wait for the final result.

I think I waited for an hour just to know my result with an authorized DOH counselor/doctor. I entered the clinic cubicle and two of them were with me: the Hi-Precision nurse and the doctor/counselor. They started the conversation with a pre-counseling. But my mind couldn’t grasp the torture of waiting for what the result may be. I didn’t deserve such torture of prolonged suspense! I cut them short and asserted myself by being in control. I told them to please open the envelope first then we proceed with the so-called counseling.

And yes! The waiting was over! It’s POSITIVE.

I wanted to cry, my mind floated and it’s like my body was splash with icy water. I maintained my composure and accepted immediately my fate. I choose to be strong and took responsibility for myself. There’s no one to be blamed because I defined my lifestyle, choosing all the actions not in accord.

I didn’t waste time and I called the attention of both the nurse and the doctor to be realistic in handling a patient who is positive. Too much prolonged suspense can truly kill you. I taught them a lesson to be straight-forward the next time, and to be constructive. I guess they were more emotional than me. It truly created a great pain in my heart. The waiting is unacceptable! And I told them to be more responsible with their duty; to empathically feel what a HIV-positive person may feel.

That afternoon, the first thing I did was to drive to the cemetery. I felt that my life will soon pass. I was so lonely, so depressed. I visited my departed relatives in the cemetery and told them that I will be with them soon. I cried as if I was a helpless child. I prayed to the Lord to give me the strength that I needed, to comfort me in my lowest moment. And yes, He did comfort me….

ACCESSING TREATMENT

As I read the sealed enveloped sent by the Department of Health, now as one of the numerous HIV positive individuals in the country, I acquired my personal code number. This saddened me so much! It was like a prison number in Les Miserable that was going to be with me in my lifetime.

The enveloped contain the treatment hub from different regions where I can get the anti-retroviral (ARV) medicines for free.

I chose a private hospital where I can receive the free treatment to prevent the spread of the HIV virus in my body so it will no longer progress to AIDS. Well, I am lucky that these medicines are now available. I cannot imagine having this disease 30 years ago. Otherwise, it would have been an automatic death sentence.

The first time I met her, my attending doctor was very pleasant and she told me to undergo a laboratory procedure to know my CD4 – it measures my immune system versus the level or stage of infection from the HIV virus.

My good doctor gave me three type of medicine (since I learned that I was co-infected with Hepatitis B). She prescribed Efavirenz (600mg), Lamivudine (300mg) and Tenofovir Disoproxil Fumarate (300mg). To date, the said medicine is now 3-in-1, so I must just take one caplet a day before I go to bed. It’s like taking a sleeping pill, literally.

I religiously went to my doctor and cooperated with her for my well-being. At first, I felt extreme paranoia when seeing people, from the doctor’s secretary, the pharmacist and the staff in a treatment hub (RITM). I felt somehow “different”… not normal from the rest. It felt like having leprosy during the days when it had no cure; when society isolated you from the rest. A stigma! A curse! That’s how I felt…

But with my healthy mental attitude I moved forward and conditioned myself as if “its okay”… “its okay!” I cannot disclose my status to anyone. I’m too afraid of rejection. And the only best thing to do is to move forward…

I call all the saints and the holy angels to be with me always. I pray to God to give me the strength I need, to comfort me, to heal me and to be with me always. But the reality is, I am HIV positive and the cure is not yet available.

The first time I took the medicine, I totally lost my locomotor function. I had a car accident and my mind was floating. Thank God I am still alive and no one got hurt from the accident. Somehow I can relate that experience to overdosing on illegal drug. Because the body is still adjusting to the drug dosage, it felt like you’re drifting, your mind is not there, you are not in control. There was a lack of focus and concentration, or the feeling of experiencing dementia. This adjustment lasted for months and it truly affected my work because of the feeling of drifting.

My doctor gave me several vaccines to boost my immune system. HPV vaccine (although I am a top), pneumonia, flu vaccine, tetanus, et cetera. This is the only way to keep me going in life and be healthy.

Until my CD4 reached the normal range and my doctor declared that I am physically healthy! This truly made me happy!

But my dilemma didn’t end there. I still had symptoms of having a weak immune system. Sometimes I had skin rashes and had to go to a doctor who specialized with an allergy. All I know is that I have an allergy. I found out it’s herpes zoster. It gave me a burning sensation, made me itchy and had watery skin breakouts located in my upper abdomen. I learned that it’s linked to a weak immune system and the best candidate is a person with a HIV. Wow!

The doctor gave me six kinds of medicines that I should take twice a day (morning and evening). Valtrex 500mg, Gabix 100mg, Dolcet 325mg, B- complex for my nerves, Medrol 4mg and Cefalexin 500mg (optional in case a puss might appear).

DIFFERENT AND AFRAID

All throughout, I felt truly sorry for myself; but at the same time, I had no choice but only to remain strong and courageous to what lies ahead. To be connected with my BIG God. Yes, I learned a lot of lessons from my mistake. No one to be blamed. For being too “adventurous” during my younger years. For being so daring as if the pleasure of the flesh has no payback. I didn’t care as long as I was happy, “gratified”…. such a self-centered me! Take note that with all my efforts of having safe sex, I still became positive.

I cannot disclose my condition to my friends because I am too afraid of their judgement. I am too afraid and paranoid with what they will think about me. It took me some time to disclose my status to my family, whom I know will accept whatever condition and situation I will be into.

And yes, only my family embraced my real situation. I first told my younger sister, then my mom. Not so much talk… Not much explaining why, where, when, with whom. They simply embraced and comforted my troubled spirit.

RESPONSIBILITY LIVING WITH HIV

Now, I believe that I have the responsibility to educate my fellow PLU (“people like us”, a term used to refer to other men who have sex with men, particularly members of the LGBT community – Ed). Whether you are a gay, bi or transgender, I wish each and everyone of you a good life and good health. We all deserve to be happy, to be loved and experience loving sincerely by another person.  I believe love is the most powerful of all because it can take away all kinds of fear. And I cling to the most powerful love of all… and that is God’s love.

But let me remind you my friend to be responsible enough. To have safe and clean sex (lovemaking). Don’t be a daredevil because you may just find yourself someday with a “code number” from the health department.

And to those who are diagnosed to be HIV positive, I want to tell you that there is life after HIV.

Suicide? Too much worry? Extreme depression? I believe it is normal at first. But let me tell you, the choice of being and living life to the fullest, to be healthy, to be able to reach out is a choice! To be a responsible individual is a must! I am sharing you all these because I am in the situation and I cannot turn back the hands of time when I was free from this dreaded disease. But one thing certain is I can be of help to those who need advise, empower to uplift the weary soul, and a friend who will listen from the heart without any judgement.

No one else knows the feeling of being ridiculed, discriminated and isolated but from a person who is in the same boat.

I hope and pray that the cure for this disease is on its way. For now the best cure is for you to be informed, or to abstain from sex, or be faithful to your partner, or have safe sex by using condom.

Life must go on and it has in store a lot of good things for us. Define your true purpose in life that you may be whole.

POZ

New cause of inflammation in people with HIV identified

While current antiretroviral treatments for HIV are highly effective, data has shown that people living with HIV appear to experience accelerated aging and have shorter lifespans – by up to five to 10 years – compared to people without HIV. These outcomes have been associated with chronic inflammation, which could lead to the earlier onset of age-associated diseases.

Published

on

Photo by @cottonbro from Pexels.com

While current antiretroviral treatments for HIV are highly effective, data has shown that people living with HIV appear to experience accelerated aging and have shorter lifespans – by up to five to 10 years – compared to people without HIV. These outcomes have been associated with chronic inflammation, which could lead to the earlier onset of age-associated diseases, such as atherosclerosis, cancers, or neurocognitive decline.

A new study led by researchers at Boston Medical Center examined what factors could be contributing to this inflammation, and they identified the inability to control HIV RNA production from existing HIV DNA as a potential key driver of inflammation. Published in The Journal of Infectious Diseases, the results underscore the need to develop new treatments targeting the persistent inflammation in people living with HIV in order to improve outcomes.

After infection, HIV becomes a part of an infected person’s DNA forever, and in most cases, infected cells are silent and do not replicate the virus. Occasionally, however, RNA is produced from this HIV DNA, which is a first step towards virus replication. Antiretroviral treatments help prevent HIV and AIDS-related complications, but they do not prevent the chronic inflammation that is common among people with HIV and is associated with mortality.

“Our study set out to identify a possible association between HIV latently infected cells with chronic inflammation in people with HIV who have suppressed viral loads,” said Nina Lin, MD, a physician scientist at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM).

For this study, researchers had a cohort of 57 individuals with HIV who were treated with antiretroviral therapy. They compared inflammation in the blood and various virus measurements among younger (age less than 35 years) and older (age greater than 50 years) people living with HIV.

They also compared the ability of the inflammation present in the blood to activate HIV production from the silent cells with the HIV genome. Their results suggest that an inability to control HIV RNA production even with antiretroviral drugs correlates with inflammation.

Antiretroviral treatments help prevent HIV and AIDS-related complications, but they do not prevent the chronic inflammation that is common among people with HIV and is associated with mortality.

“Our findings suggest that novel treatments are needed to target the inflammation persistent in people living with HIV,” said Manish Sagar, MD, an infectious diseases physician and researcher at BMC and the study’s corresponding author. “Current antiretroviral drugs prevent new infection, but they do not prevent HIV RNA production, which our results point as a potential key factor driving inflammation in people living with HIV.”

According to the Centers for Disease Control and Prevention, it is estimated that 1.2 million Americans are living with HIV; however, approximately 14 percent of these individuals are not aware that they are infected.

Another CDC reporter found that of those diagnosed and undiagnosed with HIV in 2018, 76 percent had received some form of HIV care; 58 percent were retained in care; and 65 percent had undetectable or suppressed HIV viral loads. Antiretroviral therapy prevents HIV progression and puts the risk of transmission almost to zero.

The authors note that these results need to be replicated in larger cohorts. “We hope that our study results will serve as a springboard for examining drugs that stop HIV RNA production as a way to reduce inflammation,” added Sagar, also an associate professor of medicine and microbiology at BUSM.

Continue Reading

POZ

Global HIV response is neglecting gay and bi men, and trans women – study

To date, gay and bisexual men account for about one in five new HIV infections. However, they were only allocated approximately 2% of the $57 billion in global donor funding to treat the virus and combat its spread between 2016 and 2018.

Published

on

Photo by @cottonbro from Pexels.com

Funding to fight HIV among gay and bisexual men, as well as transgender women is just a fraction of what it should be. This is according to researchers from Dutch HIV charity Aidsfonds.

To date, gay and bisexual men account for about one in five new HIV infections. However, they were only allocated approximately 2% of the $57 billion in global donor funding to treat the virus and combat its spread between 2016 and 2018.

Meanwhile, while trans people represented about 1% of new global HIV infections in 2018, programs targeting them received only 0.06% of the total funding.

The Aidsfonds report stated that globally, the total number of new HIV infections hasn’t declined for several years, stagnating at 1.7 million in 2018. This is above the global target of 500,000 per year by 2020, and can even be a reflection of a worsening picture for key populations.

Between 2016 and 2018, the total combined resources for the HIV response was approximately $57.3 billion. In the same period, the total funding of HIV programs for key populations is estimated at around US$1.3 billion.

This means that “programs targeting key populations received only 2% of all HIV funding, even though key populations accounted for over half of all new infections in 2018.”

In 2016, UNAIDS estimated that $6.3 billion was needed for the delivery of comprehensive service packages for key populations between 2016 and 2018. Another $551 million was required for the distribution of pre-exposure prophylaxis (PrEP) to these communities, making a total of $6.8 billion needed.

And so “there was a staggering gap of 80% between the budget required for HIV programs targeting key populations ($6.8 billion) and the amount made available ($1.3 billion),” Aidsfonds stated.

To end the AIDS epidemic by 2030, Aidsfonds’ recommendations included:

  1. Increase of funders’ investments towards the $36.49 billion
    needed for HIV programming for key populations, over the next decade.
  2. Scale up the proportion of funding focused on community-led and community-based interventions.
  3. Increase the proportion of funding for advocacy and support to key populations to create enabling environments.
  4. Undertake concerted and coordinated efforts to systematically disaggregate, track and make public, funding allocation and spending for key population HIV programming.
Continue Reading

POZ

Stereotypes and discrimination contribute to HIV-related stigma among nursing staff

Faculty attitudes about caring for PLHIV can impact student attitudes and the care they provide.

Published

on

Photo by Anna Shvets from Pexels.com

In December 2012, Xander (not his real name) was tested HIV-positive. And he recalled that during one of his visits to his treatment hub in Metro Manila, “there was this one nurse who told me: ‘Now you’re HIV-positive; stop having sex and stop increasing your numbers’,” he said, adding that it was never clear to him “how to react when healthcare providers themselves stigmatize and discriminate.”

But HIV-related stigma and discrimination among healthcare providers – e.g. nurses – has been studied before, even if, according to Dr. Juan Leyva (Universitat Autonoma de Barcelona), Dr. Patrick Palmieri (Universidad Norbert Wiener and A.T. Still University), and Dr. Joan Edwards (Texas Woman’s University), this issue has not been frequently re-visited.

This is why they looked at this issue again; though this time, focusing on nursing faculty and students, believing that teaching about HIV-related stigma and discrimination may actually start in nursing schools. Particularly, they did a cross-sectional study of nursing faculty in six countries that appeared in The Open AIDS Journal.

According to them, “since the earliest study about nursing faculty and students attitudes and beliefs about caring for people living with HIV/AIDS (PLHIV) in the early 1990’s, there have only been 17 additional studies.” And so “knowledge in this area of study is still lacking to fill some gaps in understanding attitudes towards people living with the disease.”

The researchers sought to understand HIV-related attitudes of nursing faculty in three continents from six countries (Canada, Colombia, England, Peru, Spain, and the US) and how it correlates to three dimensions of prejudice, stereotypes and discrimination.

The researchers found that HIV-related stigma about caring for PLHIV are slightly positive with notable differences between countries. Apart from Peru, and to a lesser extent neighboring Colombia, the results are consistent with other findings from a few smaller studies. The results can be explained, among other reasons, by the high HIV-related stigma in South America and the pervasive discrimination experienced by the LGBTQ community. Although myths and knowledge deficits about HIV/AIDS remain problematic, the results appear to be influenced by nationality in terms of prejudices, stereotypes, and discrimination.

Faculty attitudes about caring for PLHIV can impact student attitudes and the care they provide. According to Dr. Palmieri, “nursing faculty attitudes can become part of an informal curriculum where implicit learning is impregnated with personal values.”

The researchers note that in terms of HIV/AIDS education, faculty might not be comfortable teaching what they do not understand. The researchers conclude that theory-derived, evidence-informed interventions need to be developed to advance the knowledge and attitudes of nursing faculty about caring for people living with HIV. The researchers plan to attempt to address negative attitudes with a stigma-reduction intervention based on the information from similar studies.

For the likes of Xander, “healthcare providers need to be more sensitive to the plight of PLHIV. Otherwise, they become part of the problem, not the solution.”

Continue Reading

POZ

HIV-1-specific immune cells can recognize viral particles with capacity to rebound following ART interruptions

Majority of these immune cells, called CD8+ T cells, should have the capacity to detect the HIV-infected cells that drive HIV-1 rebound following interruptions to treatment. This insight could contribute to the development of new curative strategies against HIV infection.

Published

on

Photo by Miguel Á. Padriñán from Pexels.com

Immune cells that can recognize residual HIV-infected cells in people living with HIV (PLWH) who take antiretroviral therapy (ART) remain active for years, says a study published in eLife.

The findings also suggest the majority of these immune cells, called CD8+ T cells, should have the capacity to detect the HIV-infected cells that drive HIV-1 rebound following interruptions to treatment. This insight could contribute to the development of new curative strategies against HIV infection.

ART has transformed HIV-1 from a fatal disease to a chronic condition in PLWH. However, it must be taken by those with the infection for the rest of their lives, as interrupting treatment often allows the virus to rebound within weeks. This rebound results from cells harbouring HIV-1 DNA that is integrated into the human genome.

“While more than 95% of proviral DNA is unable to replicate and reactivate HIV-1, the remaining fraction that we define in our study as the ‘HIV-1 reservoir’ maintains its ability to produce infectious virus particles and cause viral rebound,” explains lead author Joanna Warren, Postdoctoral Investigator at the Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, US. “The largest and most well-characterized HIV-1 reservoir resides in ‘resting’ CD4+ T cells, which circulate in the blood and are long-lived.”

T cells likely help to control viral rebound and could be leveraged in future treatment strategies against HIV.

There are a couple of strategies to allow people with HIV-1 to stop ART without viral rebound. Both approaches may harness HIV-1-specific CD8+ T cells to achieve the reduction or elimination of the HIV-1 reservoir. However, variations (or mutations) in viral particles that exist in the HIV-1 reservoir may limit the capacity of these T cells to recognise and clear virus-infected cells, meaning the cells can escape detection and go on to cause viral rebound. “In our study, we wanted to determine the frequency and patterns of T-cell escape mutations in the HIV-1 reservoir of people who are on ART,” Warren says.

To do this, the team measured HIV-1-specific T-cell responses and isolated reservoir virus in 25 PLWH who are on ART. Of these participants, four started on ART during acute HIV-1 infection, which means virus levels were controlled early, while the other 21 started on ART during chronic HIV-1 infection, which means considerable virus mutation occurred before virus levels were controlled.

In the HIV-1 proteome (the entire set of proteins expressed by the virus) for each participant, the team identified T-cell epitopes (regions of proteins that trigger an immune response). They sequenced HIV-1 ‘outgrowth’ viruses from resting CD4+ T cells and tested mutations in T-cell epitopes for their effect on the size of the T-cell response. These strategies revealed that the majority (68%) of T-cell epitopes did not harbor any detectable escape mutations, meaning they could be recognized by circulating T cells.

“Our findings show that the majority of HIV-1-specific T cells in people on ART can detect HIV viruses that have the capacity to rebound following treatment interruption,” concludes senior author Nilu Goonetilleke, a faculty member at the Department of Microbiology and Immunology, University of North Carolina at Chapel Hill. “This suggests that T cells likely help to control viral rebound and could be leveraged in future treatment strategies against HIV.”

Continue Reading

POZ

Study links low immunity to poor outcomes in patients with HIV who contract COVID-19

“When we have vaccines, our goal is to identify the most vulnerable populations. Patients with HIV should be a priority target when we are looking at any measure that could improve outcomes for patients at high risk for complications with COVID-19.”

Published

on

Photo by @marjanblan from Unsplash.com

Clinical trials are testing whether medications that treat human immunodeficiency virus (HIV) can also treat COVID-19, leading some patients with HIV to believe they might be protected against the coronavirus. But a researcher from the MU School of Medicine not only found patients with HIV are susceptible to the virus, she also discovered which factors increased the risk of hospitalization and death.

Principal investigator Dima Dandachi, MD, assistant professor of clinical medicine, examined data that included 286 adult patients with HIV who were diagnosed with COVID-19 across 36 institutions in 21 states. Within 30 days of COVID-19 diagnosis, 57% of the patients required hospitalization, 16% required ICU admission and 9% did not survive. In the study, more than 94% of patients were actively taking HIV medication.

“We were able to show that patients with HIV who are actively taking their medication are just as susceptible to COVID-19 as the general public,” Dandachi said. “And those with low immunity uncontrolled HIV or newly diagnosed HIV are at a higher risk of hospitalization or death. The key message for these patients is to take precautions against contracting the virus while ensuring they are compliant with their HIV medications to raise their immune cell count as high as possible.”

Dandachi and her team of researchers found people with HIV older than 60 and those with chronic health issues also had a much higher risk of being hospitalized or dying from COVID-19.

“The medications that prolong the lives of patients with HIV have improved life expectancy, but now we are seeing these patients develop other chronic conditions such as obesity, diabetes and heart disease that we didn’t see 15 years ago,” Dandachi said. “And when we looked at the data from this study, we found that lung disease, kidney disease, hypertension and older age were associated with higher hospitalization rates, higher ICU admissions and increased mortality from COVID-19.”

As a researcher-clinician who treats patients with HIV, Dandachi will use this study to counsel her patients to best protect themselves against COVID-19 while also using it as proof that this patient population should be among the first considered for protection once a vaccine is developed.

“When we have vaccines, our goal is to identify the most vulnerable populations,” Dandachi said. “Patients with HIV should be a priority target when we are looking at any measure that could improve outcomes for patients at high risk for complications with COVID-19.”

Dandachi’s study, “Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19,” also featured contributions from Mojgan Golzy, PhD, an assistant research professor in the Department of Health Management and Informatics; and MU School of Medicine students Grant Geiger and Maraya Camazine. It was published by the journal Clinical Infectious Diseases.

Continue Reading

POZ

Study supports WHO recommendation to use dolutegravir as first-line HIV treatment; efavirenz an alternative option

A study supports the current recommendation from the World Health Organization to use dolutegravir as first-line treatment for HIV, with efavirenz as an alternative option. However, the study also suggests that dolutegravir should be combined with TDF/FTC, which is associated with suppression of weight gain.

Published

on

A study supports the current recommendation from the World Health Organization to use dolutegravir as first-line treatment for HIV, with efavirenz as an alternative option. However, the study also suggests that dolutegravir should be combined with TDF/FTC, which is associated with suppression of weight gain, and not with the newer combination of TAF/FTC, which is associated with excess weight gain and clinical obesity, especially in women.

For the ADVANCE research study, conducted in central Johannesburg in South Africa, over 1,000 participants were recruited from routine HIV services in and around the inner city area of Hillbrow. Data was cross-analyzed with two of the current Department of Health antiretroviral regimens, recommended in the 2019 ART guidelines, and a third regimen favored by higher-income countries. The newer regimens appeared to have side effect and resistance benefits over older regimens, and potential cost benefits, but little research had been done on non-Western populations with them.

All three regimens were very potent and well tolerated by patients; however, the newer regimens containing dolutegravir (DTG) and tenofovir alafenamide (TAF) demonstrated a large increase in weight, especially in women.

After 96 weeks of treatment, the percentage of people with viral suppression was 79% in the TAF/emtricitabine (FTC)+DTG arm, 78% in the TDF (tenofovir disoproxil fumarate)/FTC+DTG arm and 74% in the TDF/FTC/EFV (efavirenz) arm.

There were no significant differences in overall efficacy between the three treatments tested.

In terms of weight gain, after 96 weeks of treatment, men gained 5.4 kg in the TAF/FTC+DTG arm, 3.6 kg in the TDF/FTC+DTG arm, and 1.1 kg in the TDF/FTC/EFV arm.

For women, at the same time point, the weight gain was 8.1 kg in the TAF/FTC+DTG arm, 4.8 kg in the TDF/FTC+DTG arm, and 3.2 kg in the TDF/FTC/EFV arm.

The treatment emergent obesity for women at week 96 was 28% for those on TAF/FTC+DTG (5% for men), 18% for those on TDF/FTC+DTG (4% for men), and 12% for those on TDF/FTC/EFV (3% for men).

Dr Simiso Sokhela, lead clinician on the study, commented: “We are concerned about the weight gain and body composition changes which are more severe in women, and we have predicted new risk of associated diabetes and other complications, especially when taking both TAF and DTG together. The 96 week results supports the WHO treatment guidelines which reserve TAF only for patients with osteoporosis or impaired renal function.”

The study team suggest that service providers should consider the best options for patients to reduce their risk of long-term co-morbidities, and should consult with patient groups, researchers and other expert groups for guidance.

Continue Reading
Advertisement
Advertisement

LIKE US ON FACEBOOK

Most Popular